| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00432-019-02914-2 |
| P698 | PubMed publication ID | 31006846 |
| P50 | author | Jens Bedke | Q41700368 |
| Steffen Rausch | Q88347217 | ||
| P2093 | author name string | Arnulf Stenzl | |
| Elke Schaeffeler | |||
| Matthias Schwab | |||
| Falko Fend | |||
| Jörg Hennenlotter | |||
| Marcus Scharpf | |||
| Stephan Kruck | |||
| Eva Neumann | |||
| Kathleen Freitag | |||
| Peter Klaiber | |||
| P2860 | cites work | Pharmacogenomics in the clinic | Q26782786 |
| Pharmacogenomics of statins: understanding susceptibility to adverse effects | Q28079822 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| The association between statin medication and progression after surgery for localized renal cell carcinoma | Q34206127 | ||
| The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. | Q34216710 | ||
| Mechanisms and assessment of statin-related muscular adverse effects | Q34570995 | ||
| Statin use and reduced cancer-related mortality | Q34645107 | ||
| Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? | Q34749837 | ||
| Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma | Q34757109 | ||
| EAU guidelines on renal cell carcinoma: 2014 update. | Q35548292 | ||
| Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial | Q35583876 | ||
| Hypertension pharmacogenomics: in search of personalized treatment approaches | Q36652960 | ||
| Statin myotoxicity: a review of genetic susceptibility factors | Q38157284 | ||
| Statin use and kidney cancer outcomes: A propensity score analysis. | Q38900200 | ||
| Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. | Q41035635 | ||
| The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. | Q41380085 | ||
| In silico drug repositioning: what we need to know | Q44525419 | ||
| Ki67 targeted strategies for cancer therapy. | Q45873470 | ||
| Computational Drug Repositioning using Low-Rank Matrix Approximation and Randomized Algorithms | Q47557040 | ||
| Genetic variation in human drug-related genes. | Q47564586 | ||
| Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery. | Q53612763 | ||
| Adjuvant therapy for advanced renal cell carcinoma | Q57178071 | ||
| Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice | Q86547521 | ||
| Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review | Q91102477 | ||
| Re: Maxine Sun, Lorenzo Marconi, Tim Eisen, et al. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol 2018;74:611-20: Systematic Review Findings on the Role of Adju | Q93356271 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1835-1843 | |
| P577 | publication date | 2019-04-22 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation | |
| P478 | volume | 145 |
Search more.